In Simple Terms
Alzheimer’s can affect more than memory: sleep, appetite, and the body’s response to stress may also change. A new study found that a small brain region involved in controlling these functions changes in different ways with age and Alzheimer’s. The findings offer researchers new leads, but they do not yet explain what causes the changes or how to treat them.
A Small Region with a Wide Reach
Research on Alzheimer’s has long focused on brain regions involved in memory and thinking. But disrupted sleep, changes in appetite, shifts in the body’s daily rhythm, and altered responses to stress are reminders that the disease affects more than memory. At the base of the brain lies the hypothalamus, a small structure that plays a central role in regulating the body’s functions. A study published in Nature offers a more detailed map of what happens in this control center during aging and the early stages of Alzheimer’s.
The hypothalamus is made up of specialized units called nuclei, each with distinct roles. The suprachiasmatic nucleus, or SCN, helps set the body’s daily clock, while the arcuate nucleus, or ARC, helps regulate appetite and energy balance. Other nuclei are involved in hormonal responses, stress, and a range of functions that help keep the body in balance.
This region matters because people with Alzheimer’s may experience sleep problems and changes in appetite alongside memory difficulties. Some disruptions to daily rhythms may even appear before other clinical signs. Yet the hypothalamus and its cell types have not received the same detailed attention as memory-related brain regions. That led a team headed by Ashley Webb, an associate professor at the Buck Institute for Research on Aging, to ask a focused question: Can early changes be detected in the hub that regulates these functions, and can researchers pinpoint where they occur and which cells are involved?
This does not mean that every change in sleep or appetite is a sign of Alzheimer’s; many factors can affect these functions. But it opens the door to examining the disease from a broader perspective, connecting brain changes with symptoms families may notice in everyday life. The researchers report that an estimated 10 to 30 percent of people over the age of 65 are affected by the disease.
A Map That Combines Two Different Views
The team created a research resource called HypoAD, combining brain imaging with measurements of gene activity in cells. Bringing the two methods together was more than a technical detail: it offered two complementary ways to examine the hypothalamus. Imaging shows the shape and size of brain regions in living people, while cell analysis reveals which genes are active in different cell types, but requires tissue samples.
To measure brain-region volumes, the researchers analyzed MRI scans from 458 adults. They used a high-resolution atlas to identify 13 subregions of the hypothalamus and measure each one. Participants were grouped according to their cognitive abilities and levels of amyloid-beta, a protein associated with the plaques found in Alzheimer’s. This made it possible to compare patterns across different groups rather than treating the hypothalamus as one undifferentiated mass.
The molecular part of the map drew on an analysis of about 614,000 cell nuclei from hypothalamic tissue collected after death. The samples included seven people whose disease was mostly at an early stage and seven people of a similar age who did not have dementia, as well as published data from three younger people. This approach allows researchers to estimate which genes are active in each cell, helping them link changes to specific cell types rather than describing a general shift across brain tissue.
To see how well the findings held up, the researchers compared them with protein measurements in spinal fluid, gene-expression data from the prefrontal cortex covering about 800 donors, maps showing where genes are active in tissue, and a mouse model of Alzheimer’s. However, the MRI scans and cell samples did not come from the same people. The comparisons therefore let researchers consider the findings side by side, but cannot prove a direct link between the size of a particular region in an individual and the activity of its cells.
Aging Does Not Change the Whole Hypothalamus in the Same Way
Imaging measurements showed little change in the hypothalamus’s overall volume with age, but that broad picture concealed clear differences among its parts. Older age was associated with a smaller lateral hypothalamus, while the SCN, ARC, and several other nuclei grew larger. These included the paraventricular nucleus, the periventricular nucleus, and the dorsomedial hypothalamic nucleus, known as the DMH.
The pattern remained after the researchers accounted for Alzheimer’s status, suggesting that some differences reflect normal aging rather than the disease alone. This is where dividing the hypothalamus into smaller units proved useful: a measurement of total volume would have made the region appear almost unchanged, while closer analysis revealed that some parts shrink and others grow. A larger volume does not necessarily mean that a nucleus is functioning better. Imaging describes size, but by itself cannot tell whether a change is helpful or harmful.
The team also found differences associated with Alzheimer’s, amyloid-beta, or cognitive impairment. These differences were more modest than some linked to age and sex, however, and did not reach statistical significance. The current data therefore cannot establish that the size of any single nucleus is a useful diagnostic marker for the disease. More sensitive measurements or larger samples may be needed to detect subtle differences, if they exist.
One comparison in the study shows three-dimensional reconstructions of hypothalamic regions in two women, both 72 years old: one without Alzheimer’s and one with the disease. The images show differences in regions including the SCN, AN, and Pe, which are linked to sleep, daily rhythms, and metabolic regulation. But this is a visual example of differences that can be detected, not standalone proof of a pattern that applies to every patient.
Inflammation and the Body Clock Leave Clues in Cells
The team moved from measuring the nuclei’s shape to examining gene activity. Using machine-learning models, the researchers tried to distinguish cells from people with Alzheimer’s from those from people without dementia based on patterns of gene activity. The strongest signals that helped separate the groups fell into two broad areas: inflammatory responses and the regulation of daily rhythms.
Microglia, immune cells that live in the brain, stood out for having the largest number of genes whose activity had changed. When the researchers arranged the cells along a path from younger people through aging and then Alzheimer’s, the microglia appeared to shift gradually from a less active state toward a pattern associated with the disease. This is consistent with findings in other brain regions, but it does not prove that the shift causes Alzheimer’s or that it unfolds in the same order in everyone.
That caution is important because the tissue data came from different people at a single point in time, rather than from tracking the same cells over several years. The study can reveal associations and possible pathways, but it cannot establish which way the relationship runs or prove cause and effect. Even so, signs of inflammation in the hypothalamus make it another region worth examining to understand early changes in the disease.
The analysis also identified 254 neuronal subtypes. The clearest changes appeared among inhibitory neurons, including those that use GABA-based signaling, particularly in pathways involving neuropeptides and receptors. In a group of cells from the SCN, the researchers found disruptions in vasopressin signaling. Vasopressin is a molecule that helps carry signals from the body’s internal clock.
This finding gives researchers a more specific lead on the relationship between disrupted daily rhythms and Alzheimer’s. The question is not just whether sleep changes: a molecular pathway in a region known to help set daily rhythms also appears different in the early stages of the disease. But the study does not show that this change causes sleep problems, or whether altering vasopressin signaling would improve sleep or affect the course of the disease.
Bigger Cells and a Reshaped Tissue?
The study found no clear change in the total number of cells. Instead, the researchers raised the possibility that some cells may become larger or more active, with clues pointing to a possible role for mTOR, a growth-related pathway, and to changes in the material between cells. These patterns appeared alongside the activation and inflammation of glial cells. This is an interpretation of the findings, not a firm conclusion; the team described it as a hypothesis that needs further testing.
The idea helps distinguish between two different questions: Are cells disappearing from the region, or are their numbers staying roughly the same while their condition and behavior change? The available data lean toward the second possibility, although more studies are needed to provide a clear answer. Understanding what happens between cells, as well as inside them, may also help explain changes in tissue that would not show up by counting cells alone.
What the Findings Tell Us—and What They Don’t
HypoAD brings together a relatively broad imaging dataset and highly detailed molecular analysis, but it does not track people over time. Imaging covered 458 adults, while the postmortem tissue group included only 14 donors: seven with Alzheimer’s, which was mostly at an early stage, and seven of a similar age without dementia. The resource also included published data from three younger people. The small number of postmortem samples is a recognized limitation of this kind of research.
In addition, the MRI measurements and gene-sequencing data came from different groups, making it impossible to statistically link brain-region size with gene activity in the same individual. The cross-sectional design captures differences at one point in time, but cannot show how those differences developed in each person. The map should therefore be treated as a resource for guiding future questions and research—not as a ready-to-use diagnostic tool or evidence that changes in the hypothalamus start the disease.
These limitations underscore the importance of the next steps proposed by the team: tracking changes over time, then testing whether protecting the body’s daily rhythms or supporting neuropeptide signaling can ease some symptoms or slow the disease. Studying the relationship between inflammation and neurons that regulate daily rhythms may also reveal whether these pathways change together or follow separate courses.
The Bottom Line
The study offers a more detailed picture of the hypothalamus in aging and Alzheimer’s. Its overall size may remain nearly stable even as individual nuclei change in opposite directions, while cells show signs linked to inflammation and daily rhythms. Among the notable findings are altered vasopressin signaling in cells involved in the brain’s internal clock, alongside changes in microglia and inhibitory neurons. These results do not establish a cause or a treatment, but they broaden the search beyond memory-related regions and point to pathways worth investigating. Future research will need to determine whether preserving the hypothalamus’s functions can ease symptoms or influence the course of Alzheimer’s.